Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Shareholders rights

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Feb 08, 2023 1:36am

212 Views

Post# 35273607

RE:RE:Shareholders rights

The TMazz comment is completely wrong.

The BOD is there to protect our interests and legally required to do so in terms of achieving the maximum possible value. NDAs are in place from the first possible discussion.

That means: non-disclosure agreement.

I am astounded someone would post that.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities